Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy

Journal of Clinical Oncology

Volumn 23, Issue 30, 2005, Pages 7721-7735

  Cui, Xiaojiang ^a   Schiff, Rachel ^a   Arpino, Grazia ^a   Osborne, C Kent ^a   Lee, Adrian V ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLIC AMP; CYCLIN DEPENDENT KINASE 2; DOPAMINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; ESTROGEN ACTIVITY; GENE LOCUS; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; METHYLATION; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SYSTEMATIC REVIEW; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 32944482243     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.004     Document Type: Review

References (154)

1. Campos SM, Winer EP: Hormonal therapy in postmenopausal women with breast cancer. Oncology 64:289-299, 2003
2. Osborne CK, Zhao H, Fuqua SA: Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 18:3172-3186, 2000
3. Baum M, Buzdar A: The current status of aromatase inhibitors in the management of breast cancer. Surg Clin North Am 83:973-994, 2003
4. Buzdar AU: Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 8:335-341, 2003
5. Fendrick JL, Raafat AM, Haslam SZ: Mammary gland growth and development from the postnatal period to postmenopause: Ovarian steroid receptor ontogeny and regulation in the mouse. J Mammary Gland Biol Neoplasia 3:7-22, 1998
6. Allred DC, Mohsin SK, Fuqua SA: Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8:47-61, 2001
7. Saji S, Jensen EV, Nilsson S, et al: Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci U S A 97:337-342, 2000
8. Bocchinfuso WP, Korach KS: Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 2:323-334, 1997
9. Conneely OM, Jericevic BM, Lydon JP: Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 8:205-214, 2003
10. Kraus WL, Montano MM, Katzenellenbogen BS: Cloning of the rat progesterone receptor gene 5′-region and identification of two functionally distinct promoters. MoI Endocrinol 7:1603-1616, 1993
11. Li X, Lonard DM, O'Malley BW: A contemporary understanding of progesterone receptor function. Mech Ageing Dev 125:669-678, 2004
12. Lydon JP, DeMayo FJ, Conneely OM, et al: Reproductive phenotpes of the progesterone receptor null mutant mouse. J Steroid Biochem Mol Biol 56:67-77, 1996
13. Shyamala G, Yang X, Cardiff RD, et al: Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci U S A 97:3044-3049, 2000
14. Hopp TA, Weiss HL, Hilsenbeck SG, et al: Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10:2751-2760, 2004
15. De Vivo I, Hankinson SE, Colditz GA, et al: A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 63:5236-5238, 2003
16. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
17. McGuire WL: Hormone receptors: Their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5:428-433, 1978
18. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973-1979, 2003
19. Hull DF, Clark GM, Osborne CK, et al: Multiple estrogen receptor assays in human breast cancer. Cancer Res 43:413-416, 1983
20. Gross GE, Clark GM, Chamness GC, et al: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44:836-840, 1984
21. Balleine RL, Earl MJ, Greenberg ML, et al: Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 79:1564-1571, 1999
22. Potter JD, Cerhan JR, Sellers TA, et al: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: How many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 4:319-326, 1995
23. Anderson WF, Chatterjee N, Ershler WB, et al: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76: 27-36, 2002
24. Colditz GA, Rosner BA, Chen WY, et al: Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96:218-228, 2004
25. Arpino G, Weiss H, Lee AV, et al: Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261, 2005
26. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 re-currences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
27. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001
28. Hutchins L, Green S, Ravdin L: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup trial INT0102. Proc Am Soc Clin Oncol 17:1a, 1998 (abstr 2)
29. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000
30. Osborne CK, Yochmowitz MG, Knight WA III, et al: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884-2888, 1980
31. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
32. Ferno M, Stal O, Baldetorp B, et al: Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels: South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 59:69-76, 2000
33. Lamy PJ, Pujol P, Thezenas S, et al: Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res Treat 76:65-71, 2002
34. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992
35. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 - and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
36. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452-8458, 2001
37. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
38. Dowsett M, on behalf of the ATAC trialists group: Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 82:S7, 2003 (suppl 1)
39. Horwitz KB, McGuire WL, Pearson OH, et al: Predicting response to endocrine therapy in human breast cancer. Science 189:726-727, 1975
40. Konecny G, Pauletti G, Pegram M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142-153, 2003
41. Bamberger AM, Milde-Langosch K, Schulte HM, et al: Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: Correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Norm Res 54: 32-37, 2000
42. Ross JS, Fletcher JA, Bloom KJ, et al: Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell Proteomics 3:370-398, 2004
43. Arpino G, Green S, Allred DC, et al: HER-2 amplification, HER-1 expression, and tamoxifen response in ER-positive metastatic breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 10:5670-5676, 2004
44. Elledge RM, Green S, Ciocca D, et al: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4:7-12, 1998
45. Gutierrez MC, Detre S, Johnston S, et al: Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469-2476, 2005
46. Meng S, Tripathy D, Shete S, et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393-9398, 2004
47. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003
48. Shi W, Zhang X, Pintilie M, et al: Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 104:195-203, 2003
49. Perren A, Weng LP, Boag AH, et al: Immunohistochernical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253-1260, 1999
50. Garcia JM, Silva JM, Dominguez G, et al: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57:237-243, 1999
51. Cui X, Zhang P, Deng W, et al: Insulin-like growth factor-1 inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575-588, 2003
52. Campbell RA, Bhat-Nakshatri P, Patel NM, et al: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 276:9817-9824, 2001
53. Faridi J, Wang L, Endemann G, et al: Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 9:2933-2939, 2003
54. Kurokawa H, Arteaga CL: ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 9:511S-515S, 2003
55. Perez-Tenorio G, Stal O: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545, 2002
56. Parker MG: Steroid and related receptors. Curr Opin Cell Biol 5:499-504, 1993
57. Nemere I, Pietras RJ, Blackmore PF: Membrane receptors for steroid hormones: Signal transduction and physiological significance. J Cell Biochem 88:438-445, 2003
58. Horwitz KB, McGuire WL: Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 253:2223-2228, 1978
59. Beato M: Gene regulation by steroid hormones. Cell 56:335-344, 1989
60. Klein-Hitpass L, Ryffel GU, Heitlinger E, et al: A 13bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res 16: 647-664, 1988
61. Kushner PJ, Agard DA, Greene GL, et al: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317, 2000
62. Safe S: Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62:231-252, 2001
63. Xing W, Archer TK: Upstream stimulatory factors mediate estrogen receptor activation of the cathepsin D promoter. Mol Endocrinol 12: 1310-1321, 1998
64. Dobrzycka KM, Townson SM, Jiang S, et al: Estrogen receptor compressors: A role in human breast cancer? Endocr Relat Cancer 10: 517-536, 2003
65. Smith CL, O'Malley BW: Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71, 2004
66. Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/ antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666, 1997
67. Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468, 2002
68. Xu J, Li Q: Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17:1681-1692, 2003
69. Fan S, Wang J, Yuan R, et al: BHCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284:1354-1356, 1999
70. Fan S, Ma YX, Wang C, et al: Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20:77-87, 2001
71. Zwijsen RM, Wientjens E, Klompmaker R, et al: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405-415, 1997
72. Neuman E, Ladha MH, Lin N, et al: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338-5347, 1997
73. Zwijsen RM, Buckle RS, Hijmans EM, et al: Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12:3488-3498, 1998
74. McMahon C, Suthiphongchai T, DiRenzo J, et al: P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci U S A 96:5382-5387, 1999
75. Lee AV, Cui X, Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7:4429s-4435s, 2001
76. Smith CL, Conneely OM, O'Malley BW: Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc Natl Acad Sci U S A 90:6120-6124, 1993
77. Aronica SM, Katzenellenbogen BS: Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-1. Mol Endocrinol 7:743-752, 1993
78. Auricchio F, Di Domenico M, Migliaccio A, et al: The role of estradiol receptor in the proliferative activity of vanadate on MCF-7 cells. Cell Growth Differ 6:105-113, 1995
79. Schiff R, Massarweh SA, Shou J, et al: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:3315-3365, 2004
80. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
81. Lee H, Jiang F, Wang Q, et al: MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol 14:1882-1896, 2000
82. Rogatsky I, Trowbridge JM, Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 274:22296-22302, 1999
83. Chen D, Washbrook E, Sarwar N, et al: Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21:4921-4931, 2002
84. Arnold SF, Obourn JD, Jaffe H, et al: Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol 9:24-33, 1995
85. Le Goff P, Montano MM, Schodin DJ, et al: Phosphorylation of the human estrogen receptor: Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458-4466, 1994
86. Joel PB, Smith J, Sturgill TW, et al: Pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18:1978-1984, 1998
87. Ali S, Metzger D, Bornert JM, et al: Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. Embo J 12:1153-1160, 1993
88. Chen D, Pace PE, Coombes RC, et al: Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 19:1002-1015, 1999
89. Arnold SF, Vorojeikina DP, Notides AC: Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J Biol Chem 270: 30205-30212, 1995
90. Lee H, Bai W: Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 22:5835-5845, 2002
91. Font de Mora J, Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20: 5041-5047, 2000
92. Wu RC, Qin J, Hashimoto Y, et al: Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-D coactivator activity by I kappa B kinase. Mol Cell Biol 22:3549-3561, 2002
93. Wu RC, Qin J, Yi P, et al: Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell 15:937-949, 2004
94. Lopez GN, Turck CW, Schaufele F, et al: Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J Biol Chem 276:22177-22182, 2001
95. Lavinsky RM, Jepsen K, Heinzel T, et al: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 95:2920-2925, 1998
96. Hong SH, Privalsky ML: The SMRT core-pressor is regulated by a MEK-1 kinase pathway: Inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol Cell Biol 20:6612-6625, 2000
97. Baek SH, Ohgi KA, Rose DW, et al: Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110:55-67, 2002
98. Levin ER: Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol Metab 10:374-377, 1999
99. Razandi M, Pedram A, Greene GL, et al: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript; Studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 13:307-319, 1999
100. Pappas TC, Gametchu B, Watson CS: Membrane estrogen receptors identified by mul-tiple antibody labeling and impeded-ligand binding. FASEB J 9:404-410, 1995
101. Li L, Haynes MP, Bender JR: Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 100: 4807-4812, 2003
102. Figtree GA, McDonald D, Watkins H, et al: Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: Relationship to acute activation of nitric oxide synthase. Circulation 107:120-126, 2003
103. Filardo EJ: Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80: 231-238, 2002
104. Tsai EM, Wang SC, Lee JN, et al: Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 61: 8390-8392, 2001
105. Stewart AJ, Johnson MD, May FE, et al: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21172-21178, 1990
106. Lee AV, Jackson JG, Gooch JL, et al: Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:787-796, 1999
107. Lee AV, Weng CN, Jackson JG, et al: Activation of estrogen receptor-mediated gene transcription by IGF-1 in human breast cancer cells. J Endocrinol 152:39-47, 1997
108. Kahlert S, Nuedling S, van Eickels M, et al: Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275:18447-18453, 2000
109. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541, 2000
110. Morelli C, Garofalo C, Bartucci M, et al: Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 22:4007-4016, 2003
111. Song RX, McPherson RA, Adam L, et al: Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and She pathway activation. Mol Endocrinol 16:116-127, 2002
112. Anderson RG: The caveolae membrane system. Annu Rev Biochem 67:199-225, 1998
113. Razandi M, Alton G, Pedram A, et al: Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 23:1633-1646, 2003
114. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst 96:926-935, 2004
115. Kumar R, Wang RA, Mazumdar A, et al: A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418:654-657, 2002
116. Chung YL, Sheu ML, Yang SC, et al: Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/ neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97:306-312, 2002
117. Wong CW, McNally C, Nickbarg E, et al: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/ Erk phosphorylation cascade. Proc Natl Acad Sci U S A 99:14783-14788, 2002
118. Vadlamudi RK, Wang RA, Mazumdar A, et al: Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem 276:38272-38279, 2001
119. Balasenthil S, Vadlamudi RK: Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 278:22119-22127, 2003
120. Xue Y, Wong J, Moreno GT, et al: NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell 2:851-861, 1998
121. Kumar R, Wang RA, Bagheri-Yarmand R: Emerging roles of MTA family members in human cancers. Semin Oncol 30:30-37, 2003
122. Bloom ND, Tobin EH, Schreibman B, et al: The role of progesterone receptors in the management of advanced breast cancer. Cancer 45:2992-2997, 1980
123. Tomlinson IP, Nicolai H, Solomon E, et al: The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J Pathol 180:38-43, 1996
124. Winqvist R, Hampton GM, Mannermaa A, et al: Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55:2660-2664, 1995
125. Lapidus RG, Ferguson AT, Ottaviano YL, et al: Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2:805-810, 1996
126. Singh A, Ali S, Kothari MS, et al: Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: A pilot study. Int J Cancer 107:700-706, 2003
127. Fuqua SAW, Allred DC, Elledge RM, et al: The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat 26:191-202, 1993
128. Mies C, Voigt W: Sequence analysis of the DNA binding domain of the estrogen receptor gene in ER (+)/PR (-) breast cancer. Diagn Mol Pathol 5:39-44, 1996
129. Liang X, Lu B, Scott GK, et al: Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol Cell Endocrinol 146:151-161, 1998
130. Ferguson AT, Lapidus RG, Baylin SB, et al: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55:2279-2283, 1995
131. Lapidus RG, Nass SJ, Davidson NE: The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3:85-94, 1998
132. Rousseau-Merck MF, Misrahi M, Loosfelt H, et al: Localization of the human progesterone receptor gene to chromosome 11q22-q23. Hum Genet 77:280-282, 1987
133. Cormier EM. Wolf MF, Jordan VC: Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res 49:576-580, 1989
134. Oesterreich S, Zhang P, Guler RL, et al: Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 61:5771-5777, 2001
135. McClelland RA, Barrow D, Madden TA, et al: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142:2776-2788, 2001
136. Horwitz KB, Mockus MB, Lessey BA: Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 28:633-642, 1982
137. Petz LN, Ziegler YS, Schultz JR, et al: Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 18: 521-532, 2004
138. Balasenthil S, Barnes CJ, Rayala SK, et al: Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 567:243-247, 2004
139. Kurokawa H, Lenferink AE, Simpson JF, et al: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60:5887-5894, 2000
140. Barhwani L, Schiff R, Mohsin SK, et al: Inhibiting the EGFR/HER2 pathway with gefitinib and/or trastuzumab restores tamoxifen sensitivity in HER-2 overexpressing tumors. Breast Cancer Res Treat 82:513, 2003 (suppl)
141. Mazumdar A, Wang RA, Mishra SK, et al: Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3:30-37, 2001
142. Song RX, Santen RJ, Kumar R, et al: Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 193:29-42, 2002
143. Schafer JM, Bentrem DJ, Takei H, et al: A mechanism of drug resistance to tamoxifen in breast cancer. J Steroid Biochem Mol Biol 83:75-83, 2002
144. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SH, et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750, 1995
145. Osborne CK, Coronado E, Allred DC, et al: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477-1482, 1991
146. Knowlden JM, Hutcheson IR, Jones HE, et al: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032-1044, 2003
147. Zhang Z, Maier B, Samen RJ, et al: Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. Biochem Biophys Res Commun 294:926-933, 2002
148. Jeng MH, Shupnik MA, Bender TP, et al: Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139:4164-4174, 1998
149. Osborne CK, Schiff R: Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12:362-367, 2003
150. Liu MM, Albanese C, Anderson CM, et al: Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277:24353-24360, 2002
151. Dufourny B, van Teeffelen HA, Hamelers IH, et al: Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. J Endocrinol 166:329-338, 2000
152. Lee AV, Gooch JL, Oesterreich S, et al: Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition. Mol Cell Biol 20: 1489-1496, 2000
153. Zhang H, Hoff H, Sell C: Insulin-like growth factor I-mediated degradation of insulin receptor substrate-1 is inhibited by epidermal growth factor in prostate epithelial cells. J Biol Chem 275:22558-22562, 2000
154. Torres-Arzayus MI, De Mora JF, Yuan J, et al: High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6:263-274, 2004